Form 8-K · Current report
Bristol Myers Squibb 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0000014272
- Accession no.
- 0000014272-26-000018
Summary
Bristol Myers Squibb reported second-quarter 2026 revenues of $13.0 billion, up 6% year over year, with Growth Portfolio revenues up 15% to $7.6 billion, and raised its full-year 2026 revenue guidance to about $49.0–$50.0 billion and non-GAAP EPS guidance to $6.75–$7.00. CEO Christopher Boerner said the growth portfolio and pipeline progress supported the increased outlook.
Key points
- Second-quarter revenues were $13.0 billion, up 6% from a year earlier, as Growth Portfolio revenues rose 15% to $7.6 billion.
- GAAP EPS was $1.62 and non-GAAP EPS was $2.04.
- Bristol Myers Squibb raised 2026 revenue guidance to a range of about $49.0 billion to $50.0 billion and increased its non-GAAP EPS range to $6.75 to $7.00.
- The FDA accepted applications for Reblozyl with concomitant JAK inhibitor therapy in myelofibrosis-associated anemia and for mezigdomide in relapsed or refractory multiple myeloma, setting PDUFA dates of March 11, 2027 and May 13, 2027, respectively.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the information contained in or connected to the Company's website is not deemed to be incorporated by reference in this Current Report on Form 8-K. Item 7.01 Regulation FD Disclosure. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.